Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Prostate Cancer
Interventions
RADIATION

hypofractionation

Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.

RADIATION

conventional

"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."

Trial Locations (12)

Unknown

Horizon Health Network - Saint John Regional Hospital, Saint John

Complexe hospitalier de la Sagamie, Chicoutimi

Hôpital de Gatineau, Gatineau

Hôpital Charles-Lemoyne, Greenfield Park

Hôpital de la Cité-de-la-santé de Laval, Laval

CHUM-Notre- Dame, Montreal

Hôpital Maisonneuve-Rosemont, Montreal

Jewish General Hospital, Montreal

CHUQ, L'Hôtel-Dieu de Québec, Québec

Centre de santé Rimouski-Neigette, Rimouski

CHUS - Hôpital Fleurimont, Sherbrooke

Centre Hospitalier régional de Trois-Rivières, Trois-Rivières

All Listed Sponsors
lead

Sir Mortimer B. Davis - Jewish General Hospital

OTHER